Incretin-based drugs fall into two main categories: DPP-4 inhibitors (like sitagliptin and linagliptin), which block the enzyme that degrades incretin hormones to boost insulin and reduce glucagon levels, and GLP-1 analogues (such as liraglutide and dulaglutide), which mimic natural GLP-1 to enhance insulin release, slow digestion, and promote satiety
It is essential to cycle GHK-Cu to maintain receptor sensitivity and avoid copper dysregulation
I took Reta, fully understanding that the FDA may crack down on it, making it unavailable until it officially gets approved
The risk associated with aprotinin in cardiac surgery
With consistent use, it enhances brightness, smooths rough patches, and promotes an even-toned appearance